蛋白酶体抑制剂硼替佐米治疗多发性骨髓瘤的分子机制  

Mechanisms of proteasome inhibitor bortezomib on the therapy of multiple myeloma

作　　者：赵娜（综述）[1] 杨俊杰（审校）[1] 

机构地区：[1]中南大学湘雅二医院血液科,长沙410013

出　　处：《白血病．淋巴瘤》2011年第11期698-700,共3页Journal of Leukemia & Lymphoma

摘　　要：泛素-蛋白酶体通路是生物体内蛋白质选择性降解的重要途径之一，它参与了细胞内许多重要的生理、生化过程。硼替佐米作为一种蛋白酶体抑制剂，可抑制多发性骨髓瘤（MM）细胞的生长并诱导肿瘤细胞凋亡，克服了传统药物的化疗耐药性。就硼替佐米治疗MM作用机制的研究进展作一综述。The ubiquitin-proteasome pathway is one of important pathways during selective protein degradation, which participates in many intracellular physiological and biochemical processes. Bortezomib, a kind of proteasome inhibitor, can inhibit cell growth and proliferation, induce cell apoptosis and overcome drug resistance in chemotherapy. The mechanisms of bortezomib on the therapy of multiple myeloma are reviewed in this paper.

关 键 词：多发性骨髓瘤 蛋白酶体抑制剂 硼替佐米 治疗 

分 类 号：R979.1[医药卫生—药品]